Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

By afschroeder • November 9, 2025

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer. Oncologist. 2025 Nov 7:oyaf371. doi: 10.1093/oncolo/oyaf371. Epub ahead of print. PMID: 41206668.

Tags: breast cancer, Endocrinology, extended-interval dosing, Hematology/Oncology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

L-arginine Results in an Artificial Increase in Creatinine

Hwang M, Han J, Lei S, Kagan I. L-arginine Results in an Artificial Increase in Creatinine. Cureus. 2025 Oct 5;17(10):e93866. doi: 10.7759/cureus.93866. PMID: 41194845; PMCID:[...]

An Unusual Case of Elevated Testosterone: When Testosterone by Dialysis Saves the Day

Garg DK, Yu R. An Unusual Case of Elevated Testosterone: When Testosterone by Dialysis Saves the Day. Cureus. 2025 Sep 30;17(9):e93597. doi: 10.7759/cureus.93597. PMID: 41179064;[...]

Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

Praw SS, Gigliotti BJ, Tessnow A, Kang H, Margulies DJ. Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated[...]